Join the Multiple Sclerosis group to help and get support from people like you.
Multiple Sclerosis News (Page 3)
Related terms: MS
aHSCT Beneficial for Most Patients With Relapsing-Remitting MS
TUESDAY, Sept. 26, 2023 – Autologous hematopoietic stem cell transplantation (aHSCT) for treatment of relapsing-remitting multiple sclerosis (RRMS) yields freedom from disease activity for most...
Gene Test Spots Those Vulnerable to Rare but Severe Side Effect of Drugs for MS, Other Conditions
WEDNESDAY, Sept. 13, 2023 – A large number of drugs used to treat everything from multiple sclerosis to blood cancers to rheumatoid arthritis may cause a rare but often-fatal condition called...
FDA Approves Tyruko (natalizumab-sztn), a Biosimilar to Tysabri
August 24, 2023 – The U.S. Food and Drug Administration today approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection for the treatment of adults with relapsing...
First Biosimilar, Tyruko, Approved to Treat Multiple Sclerosis
FRIDAY, Aug. 25, 2023 – The U.S. Food and Drug Administration approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection, for the treatment of relapsing forms of...
Patients Say Ketogenic Diet Aids Multiple Sclerosis Symptoms
MONDAY, Aug. 21, 2023 – Patients report that a ketogenic diet (KD) improves multiple sclerosis (MS) symptoms, according to a study published in the August issue of Clinical Nutrition. Emma Wetmore,...
T-Cell Tolerant Fraction Can Predict Immunotherapy Toxicity
MONDAY, Aug. 21, 2023 – The T-cell tolerant fraction predicts clinically significant immune-related adverse events (irAEs) among patients with cancer treated with immune checkpoint inhibitors...
Fatigue Correlates With Disability in Patients With Relapsing-Remitting MS
MONDAY, Aug. 14, 2023 – A lower disability rate, better physical condition, and higher daily-living activity predict lower fatigue levels in patients with relapsing-remitting multiple sclerosis...
Fatigue Can Plague People With MS. Exercise May Help
WEDNESDAY, Aug. 9, 2023 – Patients with a type of multiple sclerosis (MS) known as relapsing-remitting MS could have less fatigue if they got more active and were in better physical shape, according...
2001 to 2020 Saw Shift in Rx for Disease-Modifying Therapy for Multiple Sclerosis
THURSDAY, July 27, 2023 – Oral disease-modifying therapies (DMTs) predominated new initiations for treatment of multiple sclerosis (MS) in 2020, according to a study published online July 10 in JAMA...
The Earlier MS Is Treated, the Better
WEDNESDAY, July 26, 2023 – Patients who get treatment for multiple sclerosis at the earliest signs of disease may have a lower risk of disability later, new research suggests. Among nearly 600...
Tascenso ODT (fingolimod) Launched to Meet the Needs of Multiple Sclerosis Patients in the US Left Without Essential Patient Support
Tascenso ODT is available to dispense to US multiple sclerosis (MS) patients Tascenso ODT is bioequivalent to, but not a generic of, Gilenya® (fingolimod) capsules1,2 On March 31st 2023 the Gilenya ...
FDA Approves Briumvi (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis
NEW YORK, Dec. 28, 2022 (GLOBE NEWSWIRE) – TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the U.S. Food and Drug Administration (FDA) has approved Briumvi™ (ublituximab-xiiy), for the t...
FDA Approves Ponvory (ponesimod) for the Treatment of Adults with Relapsing Multiple Sclerosis
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved Ponvory™ (ponesimod), a once-...
Biogen Announces FDA Approval of Plegridy (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis
CAMBRIDGE, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) – Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has approved a new intramuscular (IM) injection route...
The Feverish Pricing of MS Treatments
Towards the end of March, the FDA approved two new treatments for multiple sclerosis (MS): Mayzent (siponimod) and Mavenclad (cladribine). Both represent important breakthroughs for people with...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related drug support groups
prednisone, methylprednisolone, Medrol, prednisolone, valacyclovir, Tecfidera, Gilenya, dexamethasone, Ocrevus, dimethyl fumarate, Aubagio